<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383288</url>
  </required_header>
  <id_info>
    <org_study_id>GEIS-33</org_study_id>
    <nct_id>NCT04383288</nct_id>
  </id_info>
  <brief_title>ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities</brief_title>
  <official_title>Prospective Observational Study of the Expression of ABCB1 / P-glycoprotein as a Factor for the Biological Stratification of Non-metastatic Osteosarcoma of the Extremities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Investigacion en Sarcomas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Investigacion en Sarcomas</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-authorization, observational, multicenter and prospective study in patients between 2
      and 30 years old diagnosed with non-metastatic high-grade osteosarcoma of the extremities.

      All patients included in the study will receive the initial neoadjuvant treatment prescribed
      by the doctor of each center, according to standard practice (involving methotrexate,
      cisplatin, and adriamycin). This initial treatment precedes surgical treatment.

      After surgical treatment, the histological response to neoadjuvant chemotherapy will be
      evaluated. The histological response to primary chemotherapy will be expressed as a
      percentage of tumor necrosis. In the case of tumor necrosis above 90% the patient is defined
      as a &quot;good responder&quot; in case of a lower percentage as a &quot;poor responder&quot;.

      As an adjuvant treatment, the following options may be given according to standard practice
      in each center:

        1. - If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction
           treatment, in many sites ifosfamide at high doses and MTP-PE, is incorporated in
           addition to adriamycin.

        2. - If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction
           treatment, in many centers the option of additional administration of methotrexate, CDDP
           and adriamycin will be chosen.

        3. - If there is no overexpression of ABCB1 / P-glycoprotein, the administration of
           methotrexate, adriamycin and cisplatin will be chosen in many sites.

      In some sites they will consider the non-administration of MTP-PE or the non-administration
      of high doses of ifosfamide. And, in some hospitals, they will consider administering MTP-PE
      to all patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary objective is:

      - Disease-free survival measured as a 5-year rate in patients with localized osteosarcoma
      treated, according to standard practice, with all the drugs currently registered for the
      treatment of non-metastatic osteosarcoma (methotrexate, cisplatin, adriamycin, ifosfamide,
      MTP-PE), according to ABCB1 / P-glycoprotein expression.

      The Secondary objectives are:

        -  Evaluate overall survival in a homogeneous population of patients with non-metastatic
           osteosarcoma.

        -  Disease-free survival at 2 and 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The patients will be followed in term of Overall Survival, for all the study period (expected average: 7 years)</time_frame>
    <description>The Overall Survival will be evaluated at the end of the study period (5 enrollment years and 2 years - minimum- follow-up from the last enrolled patient)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Events free survival</measure>
    <time_frame>After 2 and 3 years from the start of study</time_frame>
    <description>The events free survival will be evaluated by means of interim analysis after 2 and 3 years from the start of study. A further evaluation will be performed at the end of enrollment and after 2 years form the last enrolled patient.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Overexpression of ABCB1 / P-glycoprotein. Poor response</arm_group_label>
    <description>If there is overexpression of ABCB1 / P-glycoprotein and poor response to induction treatment, in many sites ifosfamide at high doses and MTP-PE (Muramyl tripeptide phosphatidylethanolamine), is incorporated in addition to adriamycin.
BEFORE SURGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM (Adriamycin) 75mg/m2 (3 cycles)
AFTER SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
All the product are used as commercial formulation
Other Names:
Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overexpression of ABCB1 / P-glycoprotein. Good response</arm_group_label>
    <description>If there is overexpression of ABCB1 / P-glycoprotein and a good response to induction treatment, in many centers the option of additional administration of methotrexate, CDDP (Cisplatinum) and adriamycin will be chosen.
BEFORE SURGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
AFTER SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total length treatment 44 weeks)
All the product are used as commercial formulation
Other Names:
Methotrexate Cisplatinum doxorubicin ifosfamide mifamurtide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No overexpression of ABCB1 / P-glycoprotein</arm_group_label>
    <description>If there is no overexpression of ABCB1 / P-glycoprotein, the administration of methotrexate, adriamycin and cisplatin will be chosen in many sites.
BEFORE SURGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
AFTER SURGERY TREATMENT:
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
Total length 34 weeks
All the product are used as commercial formulation
Other Names:
methotrexate cisplatin doxorubicine</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from peripheral blood samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 2 to 30 years old diagnosed with non-metastatic high-grade osteosarcoma of
        the extremities.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed histological diagnosis of high-grade osteosarcoma of the extremities.

          2. Age: from 2 to 30 years old.

          3. Localized disease (metastasis skip accepted).

          4. Normal liver, kidney and spinal function.

          5. Ventricular ejection fraction of 50%.

          6. Absence of previous surgical treatments or chemotherapy for osteosarcoma.

          7. Interval between histological diagnosis and initiation of chemotherapy not exceeding 4
             weeks.

          8. Signing of the consent form to participate in the study.

        Exclusion Criteria:

          1. Presence of lung metastases on chest CT or in other locations.

          2. Parosteal, periosteal, or secondary osteosarcoma.

          3. Contraindications of the medications prescribed in the protocol.

          4. Pregnant or lactating.

          5. Mental or social conditions that do not guarantee adequate adherence to the protocol.

          6. Not having an adequate understanding of study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Óscar Gallego, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Gros, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricio Ledesma</last_name>
    <phone>+34 971439900</phone>
    <email>ensayos@sofpromed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Vidal, Dra.</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexandra Regueiro, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Yolanda Vidal, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Regueiro, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Blay, Dra.</last_name>
    </contact>
    <contact_backup>
      <last_name>José Antonio Villegas, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Pilar Blay, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Villegas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Cubedo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Cubedo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerónimo Martínez García, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Maria Esther Llinares, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jerónimo Martínez García, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Esther Llinares, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aizpea Echebarria, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Aizpea Echebarria, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Gallego, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Nuria Pardo Garcia, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Oscar Gallego, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nuria Pardo Garcia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Valverde, Dra.</last_name>
    </contact>
    <contact_backup>
      <last_name>Luis Gros, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Claudia Valverde, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Gros, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Cruz, Dra.</last_name>
    </contact>
    <contact_backup>
      <last_name>Macarena González Cruz, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Josefina Cruz, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Macarena González Cruz, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Álvarez, Dra.</last_name>
    </contact>
    <contact_backup>
      <last_name>Cristina Mata, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rosa Álvarez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Mata, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infantil Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco José Bautista, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Francisco José Bautista, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Redondo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MªÁngeles Vaz, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>MªÁngeles Vaz, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guiomar Guitérrez, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Guiomar Gutiérrez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Luna, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Mercedes Guibelalde, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Pablo Luna, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mercedes Guibelalde, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martín Broto, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Catalina Márquez, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Javier Martín Broto, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catalina Márquez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Diaz, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Adela Cañete, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Roberto Diaz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adela Cañete, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Martínez Trufero, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Ascensión Muñoz Mellado, Dra.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Javier Martínez Trufero, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ascensión Muñoz Mellado, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

